Skip to content
Home / Companies / URGN URG
UroGen Pharma Ltd. (URGN) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest URGN Insider Trades
About UroGen Pharma Ltd. (URGN) UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Headquarters RA'ANANA, L3
Employees 291
Listed 2017
Exchange XNAS https://www.urogen.com SEC filings for URGN on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 4 85,899 $3.75M Grant or award 10 112,000 Option exercise 4 24,000
URGN Insider Transactions (Form 4) 68 39 Form 4 filings on record, the earliest from Oct 9, 2024, newest first. Filing history page 1 of 2.
Date Insider Transaction Security Shares Price Value Aug 26, 2026 JJ James A. Robinson Jr. - Director Option exercise ordinary shares 2,000
Recent URGN Form 8-K Filings 5
Recent URGN Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 20, 2026 Schoenberg Mark Officer 60,677 $2.89M View on EDGAR Jul 9, 2026 - -
URGN Insider Trading - FAQ
What is the latest insider trade for URGN? UroGen Pharma Ltd. (URGN) had 11 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for URGN runs to 39 Form 4 filings, the earliest from 2024-10-09. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying URGN stock? No insider purchases of URGN were filed in the last 90 days.
How many insiders are selling URGN stock? 4 insider sales of URGN were filed in the last 90 days, totaling $3.75M.
Where can I see URGN SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks URGN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow URGN insider buys? Create a free InsiderAlpha account and press Watch on this page to add URGN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track URGN insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free
Market cap $2.13B
P/E ratio -
Dividend yield -
Average volume 808.4K
52 week high $50.81
52 week low $15.86
Today's high $45.54
Today's low $43.39
Open $45.09
Volume 580.0K
Previous close $45.50
Shares outstanding 48.88M Market cap
$2.13B
291 employees
URGN Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 4 sales totaling $3.75M.
Most-Active URGN Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Aug 20, 2026 MS Mark Schoenberg - Officer Open-market sale ordinary shares 60,677 $47.05 $2.85M
Jul 9, 2026 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 10,000 $40.00 $400K
Jun 22, 2026 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 10,000 $35.01 $350K
Jun 22, 2026 SH Stuart Holden - Director Grant or award Stock Option (right ot buy) 20,000 $0.00 -
Jun 22, 2026 CB Cynthia M. Butitta - Director Grant or award Stock Option (right ot buy) 10,000 $0.00 -
Jun 22, 2026 LW Leana Wen - Director Grant or award Restricted Stock Unit 8,000 $0.00 -
Jun 22, 2026 LW Leana Wen - Director Grant or award Stock Option (right ot buy) 10,000 $0.00 -
Jun 22, 2026 AB Arie Belldegrun - Director Grant or award Stock Option (right ot buy) 20,000 $0.00 -
Jun 8, 2026 MS Mark Schoenberg - Officer Option exercise Ordinary Shares 10,000 - -
Jun 8, 2026 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 5,222 $27.30 $143K
Jun 8, 2026 MS Mark Schoenberg - Officer Option exercise Restricted Stock Units 10,000 $0.00 -
May 8, 2026 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 10,000 $30.00 $300K
Feb 3, 2026 JS Jason Drew Smith - Officer Open-market sale Ordinary Shares 2,654 $19.69 $52K
Feb 3, 2026 JS Jason Drew Smith - Officer Open-market sale Ordinary Shares 1,608 $19.69 $32K
Feb 3, 2026 JS Jason Drew Smith - Officer Open-market sale Ordinary Shares 3,217 $19.69 $63K
Jan 31, 2026 JS Jason Drew Smith - Officer Option exercise Restricted Stock Units 5,500 $0.00 -
Jan 31, 2026 JS Jason Drew Smith - Officer Option exercise Restricted Stock Units 3,333 $0.00 -
Jan 31, 2026 JS Jason Drew Smith - Officer Option exercise Restricted Stock Units 6,667 $0.00 -
Jan 31, 2026 JS Jason Drew Smith - Officer Grant or award Restricted Stock Units 32,609 $0.00 -
Feb 3, 2026 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 1,844 $19.69 $36K
Feb 3, 2026 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 1,843 $19.69 $36K
Feb 3, 2026 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 3,686 $19.69 $73K
Jan 31, 2026 MS Mark Schoenberg - Officer Option exercise Ordinary Shares 3,333 - -
Jan 31, 2026 MS Mark Schoenberg - Officer Option exercise Ordinary Shares 6,666 - -
Jan 31, 2026 MS Mark Schoenberg - Officer Option exercise Ordinary Shares 3,334 - -
Jan 31, 2026 MS Mark Schoenberg - Officer Option exercise Restricted Stock Units 3,333 $0.00 -
Jan 31, 2026 MS Mark Schoenberg - Officer Option exercise Restricted Stock Units 6,666 $0.00 -
Jan 31, 2026 MS Mark Schoenberg - Officer Option exercise Restricted Stock Units 3,334 $0.00 -
Jan 31, 2026 MS Mark Schoenberg - Officer Grant or award Restricted Stock Units 20,000 $0.00 -
Jan 31, 2026 CD Chris Degnan - Officer Grant or award Restricted Stock Units 32,609 $0.00 -
Nov 26, 2025 LW Leana Wen - Director Option exercise ordinary shares 2,000 - -
Nov 26, 2025 LW Leana Wen - Director Option exercise Restricted Stock Unit 2,000 $0.00 -
Nov 26, 2025 SH Stuart Holden - Director Option exercise ordinary shares 2,000 - -
Nov 26, 2025 SH Stuart Holden - Director Option exercise Restricted Stock Unit 2,000 $0.00 -
Nov 26, 2025 CB Cynthia M. Butitta - Director Option exercise Restricted Stock Unit 2,000 $0.00 -
Nov 19, 2025 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 10,000 $25.00 $250K
Oct 8, 2025 CD Chris Degnan - Officer Option exercise Ordinary Shares 4,483 - -
Oct 8, 2025 CD Chris Degnan - Officer Open-market sale Ordinary Shares 2,203 $16.85 $37K
Oct 8, 2025 CD Chris Degnan - Officer Option exercise Restricted Stock Units 4,483 $0.00 -
Sep 8, 2025 JS Jason Drew Smith - Officer Open-market sale Ordinary Shares 1,520 $19.11 $29K
Sep 7, 2025 JS Jason Drew Smith - Officer Option exercise Restricted Stock Units 3,333 $0.00 -
Sep 7, 2025 MS Mark Schoenberg - Officer Option exercise Ordinary Shares 1,667 - -
Sep 8, 2025 MS Mark Schoenberg - Officer Open-market sale Ordinary Shares 871 $19.11 $17K
Sep 7, 2025 MS Mark Schoenberg - Officer Option exercise Restricted Stock Units 1,667 $0.00 -
Aug 26, 2025 LW Leana Wen - Director Grant or award Stock Option (right ot buy) 10,000 $0.00 -
Aug 26, 2025 LW Leana Wen - Director Grant or award Restricted Stock Unit 8,000 $0.00 -
Aug 26, 2025 AB Arie Belldegrun - Director Grant or award Stock Option (right ot buy) 20,000 $0.00 -
$CORT
CORCEPT THERAPEUTICS INC
